𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effect of blood group on idiopathic thrombotic thrombocytopenic purpura

✍ Scribed by Lara Zuberi; Durga Yerasuri; Philip Kuriakose


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
64 KB
Volume
24
Category
Article
ISSN
0733-2459

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Thrombotic thrombocytopenic purpura (TTP) is a condition caused by deficiency of ADAMTS13 resulting in accumulation of ultra large Von Willebrand factor multimers (ULVWF), leading to micro thrombi in multiple organs. The varying susceptibilities of blood group antigens to ADAMTS13 have been demonstrated. A and B antigens are protective of VWF; and VWF purified from blood group O individuals has been shown to be cleaved faster by ADAMTS13 compared to VWF from blood group AB individuals. We proposed that there may be a difference in the incidence of blood groups in TTP patients compared with the general population. We felt this to be important for a life‐threatening disease with poorly understood epidemiology. We report a retrospective analysis of 74 patients presenting from 1993 to 2008 with idiopathic TTP. We studied the incidence across various blood groups and also estimated the recurrence and mortality in each group. The incidence of various blood groups were as follows: O 36%, A 36%, B 25%, and AB 2%, compared with expected frequencies in the Detroit area: O 44%, A 33% B 20%, and AB 3%. There was a trend of lower than expected frequency of blood group O. There were 24 recurrences and 14 deaths, uniform across blood groups. We hypothesized that there may be an association between blood groups and the risk of TTP; however the differences in our study were not statistically significant. Recurrence and disease specific mortality did not appear to be impacted by blood group. J. Clin. Apheresis 2009. Β© 2009 Wiley‐Liss, Inc.


πŸ“œ SIMILAR VOLUMES


Rituximab for the treatment of refractor
✍ Lydia Koulova; Doru Alexandrescu; Janice P. Dutcher; Kevin P. O'Boyle; Saji Eape πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 162 KB πŸ‘ 2 views

Three patients (one with idiopathic thrombocytopenic purpura [ITP] and two with thrombotic thrombocytopenic purpura [TTP]) were treated with rituximab (anti-CD20 chimeric antibody) at a dose of 325 mg/m 2 administered weekly after they failed standard therapies. The patient with ITP who did not resp